Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia
Advertisement

Related Content

Korea's Celltrion Posts Record-High Q1 Sales And Net Profit, Riding On Biosimilar Prospects
Korea's Celltrion Posts Record-High Q1 Sales And Net Profit, Riding On Biosimilar Prospects
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Korean Pharma Earnings Roundup: Dong-A, Green Cross Retain Leading Positions While Yuhan, LG Life, Hanmi Struggle
Korea's Celltrion Eyes Eastern Bloc For Biosimilar Expansion
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
Advertisement
UsernamePublicRestriction

Register

SC077208

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel